Clinical trials: Thalidomide, completed
Advanced Cancers
The Effects of Thalidomide on Symptom Clusters
The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.
- Trial name
- NCT00379353
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Thalidomide in Treating Patients With Thyroid Cancer
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
- Trial name
- NCT00026533
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Kenneth Ain
Multiple Myeloma
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
This study will evaluate the safety and the efficacy of the MLN-DEXAMETHASONE, MLN-DEXAMETHASONE-CYCLOPHOSPHAMIDE, or MLN- THALIDOMIDE-DEXAMETHASONE induction combinations, followed by MLN maintenance in newly diagnosed elderly…
- Trial name
- NCT02586038
- Testing
- MLN9708, Dexamethasone, Cyclophosphamide
- Where
- Italy
- Volunteers
- 175 people
- Sponsor
- Mario Boccadoro
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to…
- Trial name
- NCT00458705
- Testing
- bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Amyloidosis
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
- Trial name
- NCT00890552
- Testing
- Lenalidomide, Melphalan, Dexamethasone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
Multiple Myeloma
Effects of Exercise in Combination With Epoetin Alfa
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training…
- Trial name
- NCT00577096
- Testing
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Prostatic Neoplasm
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer.
- Trial name
- NCT00001446
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Conditions
- Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00020046
- Testing
- docetaxel, thalidomide
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
The purpose of this Phase 2 randomized study is to evaluate the efficacy and safety of treatment with a regimen of VELCADE, dexamethasone, and thalidomide (VDT) or VELCADE, dexamethasone, thalidomide, and cyclophosphamide (VDTC)…
- Trial name
- NCT00531453
- Testing
- bortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide
- Where
- Austria
- Volunteers
- 98 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Head and Neck Cancer
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.
- Trial name
- NCT00003850
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Stage I Multiple Myeloma
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01057225
- Testing
- carfilzomib, cyclophosphamide, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Mayo Clinic
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic leukemia by stopping blood flow to the tumor.
- Trial name
- NCT00006226
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
RATIONALE: Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083005
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00040937
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 141 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
The purpose of the study is to compare thalidomide + dexamethasone with bortezomib + dexamethasone in patients with multiple myeloma refractory to melphalan therapy.
- Trial name
- NCT00602511
- Testing
- Bortezomib, Thalidomide
- Where
- 27 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Nordic Myeloma Study Group
Multiple Myeloma
Thalidomide-Dexamethasone for Multiple Myeloma
Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.
- Trial name
- NCT00038090
- Testing
- Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Thalassemia
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g.
- Trial name
- Thal-Thalido (NCT03651102)
- Testing
- Thalidomide and Hydroxyurea
- Where
- Pakistan
- Volunteers
- 654 people
- Sponsor
- Blood Diseases Clinic
Hepatocellular Cancer (HCC)
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with…
- Trial name
- NCT07321613
- Testing
- Thalidomide (50mg), carmofur, compound mylabris capsule
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma
Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma.
- Trial name
- MUKEight (NCT02461888)
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 18 sites in United Kingdom
- Volunteers
- 112 people
- Sponsor
- University of Leeds
Recurrent Melanoma, Stage IV Melanoma
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT00072163
- Testing
- temozolomide, thalidomide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)